Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Translational Science"
DOI: 10.1111/cts.12546
Abstract: We evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD5718, a novel 5‐lipooxygenase activating protein (FLAP) inhibitor, in a randomized, single‐blind, placebo‐controlled, first‐in‐human (FIH) study consisting of single and multiple ascending dosing (SAD and MAD) for… read more here.
Keywords: inhibitor; azd5718 novel; activating protein; initial clinical ... See more keywords